Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Aten. prim. (Barc., Ed. impr.) ; 50(6): 340-349, jun.-jul. 2018. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-179049

RESUMO

OBJETIVO: Conocer la adecuación del tratamiento antitrombótico (TAT) a las guías de práctica clínica en pacientes con fibrilación auricular no valvular. DISEÑO: Estudio observacional prospectivo. Emplazamiento: Centros de Salud de atención primaria y Servicio de Cardiología de un Departamento de Salud de la Comunidad Valenciana, España. PARTICIPANTES: Un total de 505 pacientes con diagnóstico de fibrilación auricular no valvular en la historia clínica electrónica de atención primaria. Mediciones principales: Pacientes con TAT inadecuado, definido como aquellos con puntuación CHA2DS2-VASc ≥ 1 que no reciban anticoagulación oral, los tratados con fármacos antivitaminaK y deficiente control de la anticoagulación, la antiagregación asociada inapropiadamente con anticoagulantes, y pacientes con CHA2DS2-VASc=0 y TAT. RESULTADOS: La edad media fue 77,4 ± 10 años. El TAT se estimó inadecuado en el 58% de los casos. Los factores relacionados de forma independiente con TAT inadecuado en la muestra global fueron la edad (OR: 1,02 (1-1,04); p = 0,029), el hipotiroidismo (OR: 1,98 (1,14-3,43); p = 0,015], el antecedente de cardiopatía isquémica (OR: 1,73 (1,15-2,59); p = 0,008) y la fibrilación auricular paroxística (OR: 2,11 (1,41-3,17); p < 0,0001). CONCLUSIONES: Los datos muestran la elevada prevalencia de tratamiento antitrombótico inadecuado en la práctica diaria, así como sus diversas causas


OBJECTIVE: To determine whether antithrombotic treatment (ATT) in patients with non-valvular atrial fibrillation in a health area complies with the recommendations of current clinical guidelines. DESIGN: Prospective observational study. LOCATION: Primary Health Care Centres and Cardiology Department of a Health Department of the Valencian Community, Spain. PARTICIPANTS: A total of 505 patients with nonvalvular atrial fibrillation were included in the study. MAIN MEASUREMENTS: ATT was deemed to be inappropriate in patients with a CHA2DS2-VASc score ≥ 1 and who were not under oral anticoagulation, in patients treated with antivitaminK drugs, and poor control of oral anticoagulation, or with antiplatelet therapy inappropriately associated with anticoagulation, and in patients on ATT with a CHA2DS2-VASc score = 0. RESULTS: The median age was 77.4±10years. The ATT was considered inadequate in 58% of cases. Factors independently associated with inadequate ATT were age (OR: 1.02 (1-1.04); P = .029), hypothyroidism (OR: 1.98 (1.14-3.43); P = .015), ischaemic heart disease (OR: 1.3 (1.15-2.59); P = .008) and paroxysmal non-valvular AF (OR: 2.11 (1.41-3.17); P < .0001). CONCLUSIONS: These data underline the high prevalence of inadequate ATT in daily practice, as well its different causes


Assuntos
Humanos , Masculino , Feminino , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial/tratamento farmacológico , Fibrinolíticos/uso terapêutico , Guias de Prática Clínica como Assunto , Resultado do Tratamento , Estudos Prospectivos , Estudo Observacional
2.
Rev. colomb. cardiol ; 25(3): 185-191, mayo-jun. 2018. tab, graf
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-978224

RESUMO

Resumen Introducción: la escala SAMe-TT2R2 ha sido propuesta para predecir la calidad de la anticoagulación con antagonistas de la vitamina K. Objetivo: validar la capacidad discriminativa de la escala SAMe-TT2R2 en una cohorte de pacientes con fibrilación auricular no valvular de la vida real. Métodos: estudio observacional de pacientes con fibrilación auricular no valvular tratados con antagonistas de la vitamina K al menos seis meses. Se consideró buen control de anticoagulación un tiempo en rango terapéutico ≥ 65% estimado con el método de Rosendaal. Se evaluó la asociación entre puntuación SAMe-TT2R2 y el control de anticoagulación con regresión logística binaria. La capacidad de discriminación se analizó mediante el cálculo del valor del área bajo la curva ROC. Resultados: se incluyeron 241 pacientes de edad media 78,6±8,6 años, 53% mujeres. La media del tiempo en rango terapéutico fue 59,4±25,4%, menor según aumentó la puntuación SAMe-TT2R2. En general, la escala no mostró capacidad para discriminar los pacientes con adecuado control de anticoagulación: área bajo la curva ROC 0,57 (IC95%:0,49-0,64, p=0,06). Solo fue útil para las puntuaciones extremas, con probabilidad de buen control del 65,1% vs. 34,9%, p=0,01 para valor 0 y del 0% vs. 100%, p=0,03 para ≥ 4. La razón de disparidad de tener un tiempo en rango terapéutico <65% para puntuación ≥2 fue de 1,22 (IC95%:0,73-2,02, p=0,44). Conclusión: en una cohorte de pacientes con fibrilación auricular no valvular y datos de la vida real la escala SAMe-TT2R2 no mostró, globalmente, capacidad discriminatoria para control adecuado de anticoagulación con antagonistas de vitamina K. Solo se mostró útil para clasificar correctamente los casos con puntuaciones extremas.


Abstract Introduction: The SAMe-TT2R2 score has been proposed to predict the quality of anticoagulation with vitamin K antagonists. Objective: To validate the discriminatory power of the SAMe-TT2R2 score real-life in a patient cohort with non-valvular atrial fibrillation. Material and methods: An observational study was conducted on patients with non-valvular atrial fibrillation treated with vitamin K antagonists for at least six months. Good anticoagulation control was considered a time in the therapeutic range of ≥ 65%, estimated with the Rosendaal method. The relationship between the SAMe-TT2R2 score and the anticoagulation control was evaluated using a binary logistic regression. The discriminatory power was determined using the calculation of the value of the area under the ROC curve. Results: The study included total of 241 patients, with a mean age of 78.6±8.6 years, and 53% women. The mean time in the therapeutic range was 59.4±25.4%, low according to the increase in the SAMe-TT2R2 score. In general, the scale did not appear to have the power to discriminate patients with adequate anticoagulation control, with an area under the ROC curve of 0.57 (95% CI: 0.49-0.64, P=.06). It was only useful for extreme scores, with a probability of good control of 65.1% vs. 34.9%, P=.01 for a value of 0, and of 0% vs. 100%, P=.03 for ≥ 4. The disparity ratio of having a time in the therapeutic range of <65% for a score ≥2 was 1.22 (95% CI: 0.73-2.02, P=.44). Conclusion: In a cohort of patients with non-valvular atrial fibrillation and with real-life data, the SAMe-TT2R2 scale, did not, on the whole, show discriminatory power for the adequate control of anticoagulation with vitamin K antagonists. It only showed to be useful to correctly classify the cases with extreme scores.


Assuntos
Humanos , Feminino , Idoso , Fibrilação Atrial , Anticoagulantes , Prevenção Primária , Acenocumarol
3.
Aten Primaria ; 50(6): 340-349, 2018.
Artigo em Espanhol | MEDLINE | ID: mdl-28867157

RESUMO

OBJECTIVE: To determine whether antithrombotic treatment (ATT) in patients with non-valvular atrial fibrillation in a health area complies with the recommendations of current clinical guidelines. DESIGN: Prospective observational study. LOCATION: Primary Health Care Centres and Cardiology Department of a Health Department of the Valencian Community, Spain. PARTICIPANTS: A total of 505 patients with nonvalvular atrial fibrillation were included in the study. MAIN MEASUREMENTS: ATT was deemed to be inappropriate in patients with a CHA2DS2-VASc score ≥1 and who were not under oral anticoagulation, in patients treated with antivitaminK drugs, and poor control of oral anticoagulation, or with antiplatelet therapy inappropriately associated with anticoagulation, and in patients on ATT with a CHA2DS2-VASc score=0. RESULTS: The median age was 77.4±10years. The ATT was considered inadequate in 58% of cases. Factors independently associated with inadequate ATT were age (OR: 1.02 [1-1.04]; P=.029), hypothyroidism (OR: 1.98 [1.14-3.43]; P=.015), ischaemic heart disease (OR: 1.3 [1.15-2.59]; P=.008) and paroxysmal non-valvular AF (OR: 2.11 [1.41-3.17]; P<.0001). CONCLUSIONS: These data underline the high prevalence of inadequate ATT in daily practice, as well its different causes.


Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/complicações , Fibrinolíticos/uso terapêutico , Fidelidade a Diretrizes , Acidente Vascular Cerebral/prevenção & controle , Idoso , Fibrilação Atrial/epidemiologia , Humanos , Hipotireoidismo/complicações , Isquemia Miocárdica/complicações , Inibidores da Agregação Plaquetária/uso terapêutico , Prevalência , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...